Guide
Published Data as of
PepBank's records hold 51 peptides with a product approved by the FDA in the US, as of October 30, 2026.1,2 This count covers the peptides in PepBank's records, not every peptide drug that exists.1 The FDA approved Ozempic, a semaglutide product, in 2017, and Mounjaro, a tirzepatide product, in 2022.3,4 Another 9 peptides have a product approved only outside the US, all of them in Russia.1,5,6,7,8,9,10,11,12,13
PepBank's records hold 51 peptides with a product approved by the FDA in the US, as of October 30, 2026. The count covers only the peptides in those records, not every peptide drug that exists.1,2
The FDA approved Ozempic, a semaglutide product, in 2017, and Wegovy in 2021.3,19 The FDA approved Mounjaro, a tirzepatide product, in 2022, and Zepbound in 2023.4,20 The FDA approved Pitocin, an oxytocin product, in 1980.2
The table lists the FDA-approved products in PepBank's records for these 51 peptides, with one product on each row.1,2 A peptide with more than one FDA-approved product appears on more than one row.21,22,23 Where the record holds no year, the Year column says not in the record.24
| Peptide | Product | Where approved | Year |
|---|---|---|---|
| Abaloparatide (Tymlos) | Tymlos | US (FDA) | not in the record24 |
| ACTH (corticotropin) | Acthar Gel | US (FDA) | 195214 |
| Bremelanotide (PT-141) | Vyleesi | US (FDA) | 201925 |
| Calcitonin-salmon | Calcitonin salmon nasal spray | US (FDA) | not in the record26 |
| Cetrorelix | Cetrotide | US (FDA) | not in the record27 |
| Cosyntropin | Cortrosyn | US (FDA) | not in the record28 |
| Dasiglucagon | Zegalogue | US (FDA) | 202129 |
| Degarelix | Firmagon | US (FDA) | not in the record30 |
| Desmopressin | Ddavp | US (FDA) | not in the record31 |
| Difelikefalin | Korsuva | US (FDA) | 202132 |
| Dulaglutide (Trulicity) | Trulicity | US (FDA) | not in the record33 |
| Elamipretide (SS-31) | Forzinity | US (FDA) | 202534 |
| Enlicitide | Lipfendra | US (FDA) | 202617 |
| Erythropoietin (human) | Epogen / Procrit | US (FDA) | 198935 |
| Erythropoietin (human) | Retacrit | US (FDA) | 201836 |
| Exenatide (exendin-4) | Bydureon BCise | US (FDA) | not in the record37 |
| Exenatide (exendin-4) | Byetta | US (FDA) | not in the record38 |
| Ganirelix | Ganirelix acetate | US (FDA) | not in the record39 |
| Glucagon | GlucaGen | US (FDA) | 199840 |
| Glucagon | Baqsimi | US (FDA) | 201941 |
| Glucagon | Gvoke | US (FDA) | 201942 |
| Goserelin | Zoladex | US (FDA) | not in the record43 |
| hCG (human chorionic gonadotropin) | Pregnyl | US (FDA) | not in the record44 |
| HGH (somatotropin) | Genotropin | US (FDA) | not in the record45 |
| Histrelin | Supprelin LA | US (FDA) | not in the record46 |
| Histrelin | Vantas | US (FDA) | not in the record47 |
| IGF-1 (mecasermin) | Increlex | US (FDA) | 200548 |
| Lanreotide | Somatuline Depot | US (FDA) | not in the record49 |
| Leuprolide | Leuprolide acetate for depot suspension | US (FDA) | 201850 |
| Linaclotide | Linzess | US (FDA) | 201251 |
| Liraglutide | Victoza | US (FDA) | 201021 |
| Liraglutide | Saxenda | US (FDA) | 201422 |
| Liraglutide | Xultophy 100/3.6 | US (FDA) | 201623 |
| Lixisenatide | Adlyxin | US (FDA) | 201652 |
| Melanotan I (afamelanotide) | Scenesse | US (FDA) | 201953 |
| Methylene blue | ProvayBlue | US (FDA) | 201654 |
| Methylene blue | Methylene blue injection, generic | US (FDA) | not in the record55 |
| Nafarelin | Synarel | US (FDA) | 199056 |
| Octreotide | Sandostatin | US (FDA) | not in the record57 |
| Orforglipron | Foundayo | US (FDA) | 202615 |
| Oxytocin | Pitocin | US (FDA) | 19802 |
| Palopegteriparatide | Yorvipath | US (FDA) | 202458 |
| Pasireotide | Signifor | US (FDA) | not in the record59 |
| Pasireotide | Signifor LAR | US (FDA) | not in the record60 |
| Pegvisomant | Somavert | US (FDA) | not in the record61 |
| Plecanatide | Trulance | US (FDA) | not in the record62 |
| Pramlintide (Symlin) | Symlin | US (FDA) | not in the record63 |
| PTH 1-84 (parathyroid hormone) | Natpara | US (FDA) | 201564 |
| Rusfertide | Mimrylo | US (FDA) | 202616 |
| Semaglutide | Ozempic | US (FDA) | 20173 |
| Semaglutide | Rybelsus | US (FDA) | 201918 |
| Semaglutide | Wegovy | US (FDA) | 202119 |
| Semaglutide | Wegovy | US (FDA) | 202565 |
| Semaglutide | Ozempic | US (FDA) | not in the record66 |
| Sermorelin | Geref | US (FDA) | 199067 |
| Sermorelin | Geref | US (FDA) | 199768 |
| Setmelanotide | Imcivree | US (FDA) | 202069 |
| Somapacitan | Sogroya | US (FDA) | 202070 |
| Teduglutide | Gattex | US (FDA) | not in the record71 |
| Teriparatide (PTH 1-34) | Forteo | US (FDA) | not in the record72 |
| Tesamorelin | Egrifta | US (FDA) | 201073 |
| Tesamorelin | Egrifta WR | US (FDA) | 202574 |
| Tesamorelin | Egrifta SV | US (FDA) | not in the record75 |
| Tirzepatide | Mounjaro | US (FDA) | 20224 |
| Tirzepatide | Zepbound | US (FDA) | 202320 |
| Triptorelin (Trelstar, Decapeptyl) | Trelstar | US (FDA) | not in the record76 |
| Trofinetide | Daybue | US (FDA) | 202377 |
| Trofinetide | Daybue Stix | US (FDA) | not in the record78 |
| Vosoritide | Voxzogo | US (FDA) | not in the record79 |
PepBank's records hold 9 peptides with a product approved only outside the US, all of them in Russia.1,5,6,7,8,9,10,11,12,13 Each peptide is listed with its product name in Russia.
The list covers only the peptides in PepBank's records, not every peptide drug that exists. As of October 30, 2026, those records hold 51 peptides with a product approved by the FDA.1,2 Counting FDA approvals and approvals in Russia, the records hold 60 peptides with an approved product in the EU, Russia or the US.1,2,5
The FDA approved Foundayo, an orforglipron product, in 2026.15 The FDA approved Mimrylo, a rusfertide product, in 2026. The FDA approved Lipfendra, an enlicitide product, in 2026 too.16,17 In 2025, the FDA approved Forzinity, an elamipretide product, and Egrifta WR, a tesamorelin product.34,74
The FDA approved Ozempic, a semaglutide product, in 2017.3 The FDA approved Rybelsus in 2019 and Wegovy in 2021. Both are semaglutide products.18,19 A second record for Wegovy shows FDA approval in 2025.65 Another record for Ozempic shows FDA approval with no year in the record.66
Some peptides in the table have more than one FDA-approved product.21,22,23,73,74,75 The FDA approved Victoza in 2010, Saxenda in 2014 and Xultophy 100/3.6 in 2016, all liraglutide products.21,22,23 For tesamorelin, the FDA approved Egrifta in 2010 and Egrifta WR in 2025. Egrifta SV has FDA approval too, with no year in the record.73,74,75
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated